UK Clinical Guideline for the Prevention and Treatment of Osteoporosis

Overview

Journal Arch Osteoporos

Publisher Springer

Date 2022 Apr 5

PMID 35378630

Authors

Celia L Gregson

David J Armstrong

Jean Bowden

Cyrus Cooper

John Edwards

Neil J L Gittoes

Nicholas Harvey

John Kanis

Sarah Leyland

Rebecca Low

Eugene McCloskey

Katie Moss

Jane Parker

Zoe Paskins

Kenneth Poole

David M Reid

Mike Stone

Julia Thomson

Nic Vine

Juliet Compston

Affiliations

Soon will be listed here.

Abstract

Introduction: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013 and 2017. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older.

Methods: Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence.

Results: Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, and models of care for fracture prevention. Recommendations are made for training; service leads and commissioners of healthcare; and for review criteria for audit and quality improvement.

Conclusion: The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals involved in its management. This position paper has been endorsed by the International Osteoporosis Foundation and by the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

Citing Articles

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.

Beaudart C, Veronese N, Douxfils J, Amuthavalli Thiyagarajan J, Bolzetta F, Albanese P Osteoporos Int. 2025; .

PMID: 40047881 DOI: 10.1007/s00198-025-07440-1.

Undetected low bone mineral density in patients undergoing lumbar fusion surgery-prevalence and risk factors.

Kohli P, Hambrecht J, Zhu J, Chiapparelli E, Schonnagel L, Guven A N Am Spine Soc J. 2025; 21:100591.

PMID: 40041543 PMC: 11876750. DOI: 10.1016/j.xnsj.2025.100591.

Osteoporosis management in patients presenting to the emergency department with fragility fractures: A retrospective observational study.

Akbas E, Kara E J Diabetes Metab Disord. 2025; 24(1):71.

PMID: 40007861 PMC: 11847761. DOI: 10.1007/s40200-025-01585-w.

Temporal trends in the burden of vertebral fractures caused by falls in China and globally from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021.

Lan Z, Liu C, Wang H, Wang Y, Kan S, Jiao Y Arch Public Health. 2025; 83(1):42.

PMID: 39962620 PMC: 11831765. DOI: 10.1186/s13690-025-01500-y.

A case-control study based on the National Health and Nutrition Examination Survey to evaluate the effects of human papilloma virus on bone health in women.

Li X, Jiao G, Chen Y BMC Med. 2025; 23(1):75.

PMID: 39920637 PMC: 11806905. DOI: 10.1186/s12916-025-03909-2.

References

Leslie W, Morin S, Lix L, Johansson H, Oden A, McCloskey E . Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2011; 23(1):75-85. DOI: 10.1007/s00198-011-1747-2. View

Kahwati L, Weber R, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M . Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018; 319(15):1600-1612. DOI: 10.1001/jama.2017.21640. View

Ganda K, Puech M, Chen J, Speerin R, Bleasel J, Center J . Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis. Osteoporos Int. 2012; 24(2):393-406. DOI: 10.1007/s00198-012-2090-y. View

Adachi J, Saag K, Delmas P, Liberman U, Emkey R, Seeman E . Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-11. DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. View

Leslie W, Rubin M, Schwartz A, Kanis J . Type 2 diabetes and bone. J Bone Miner Res. 2012; 27(11):2231-7. DOI: 10.1002/jbmr.1759. View

van Geel T, van Helden S, Geusens P, Winkens B, Dinant G . Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2008; 68(1):99-102. DOI: 10.1136/ard.2008.092775. View

Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G, Siggeirsdottir K . The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. Osteoporos Int. 2021; 32(8):1547-1555. DOI: 10.1007/s00198-020-05803-4. View

Mortensen S, Mohamadi A, Wright C, Chan J, Weaver M, von Keudell A . Medications as a Risk Factor for Fragility Hip Fractures: A Systematic Review and Meta-analysis. Calcif Tissue Int. 2020; 107(1):1-9. DOI: 10.1007/s00223-020-00688-1. View

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2001; 39(12):1383-9. DOI: 10.1093/rheumatology/39.12.1383. View

10.

Bauer D, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A . Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014; 174(7):1126-34. PMC: 4409325. DOI: 10.1001/jamainternmed.2014.1232. View

11.

Andrews J, Guyatt G, Oxman A, Alderson P, Dahm P, Falck-Ytter Y . GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66(7):719-25. DOI: 10.1016/j.jclinepi.2012.03.013. View

12.

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

13.

Schuit S, van der Klift M, Weel A, de Laet C, Burger H, Seeman E . Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34(1):195-202. DOI: 10.1016/j.bone.2003.10.001. View

14.

Reid I, Horne A, Mihov B, Stewart A, Garratt E, Bastin S . Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. J Bone Miner Res. 2019; 35(1):20-27. DOI: 10.1002/jbmr.3860. View

15.

Rittmaster R, Bolognese M, Ettinger M, Hanley D, Hodsman A, Kendler D . Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000; 85(6):2129-34. DOI: 10.1210/jcem.85.6.6614. View

16.

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

17.

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

18.

Kelley G, Kelley K, Kohrt W . Exercise and bone mineral density in men: a meta-analysis of randomized controlled trials. Bone. 2012; 53(1):103-11. DOI: 10.1016/j.bone.2012.11.031. View

19.

Bhasin S, Gill T, Reuben D, Latham N, Ganz D, Greene E . A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. N Engl J Med. 2020; 383(2):129-140. PMC: 7421468. DOI: 10.1056/NEJMoa2002183. View

20.

Kanis J, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby A . The components of excess mortality after hip fracture. Bone. 2003; 32(5):468-73. DOI: 10.1016/s8756-3282(03)00061-9. View